Drug Type Bispecific antibody |
Synonyms MCLA-158, MCLA158 |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), LGR5 antagonists(Leucine-rich repeat-containing G-protein coupled receptor 5 antagonists) |
Therapeutic Areas |
Inactive Indication- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 3 | United States | 25 Sep 2024 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Japan | 25 Sep 2024 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Argentina | 25 Sep 2024 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Australia | 25 Sep 2024 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Belgium | 25 Sep 2024 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Brazil | 25 Sep 2024 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Canada | 25 Sep 2024 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Chile | 25 Sep 2024 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 3 | France | 25 Sep 2024 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Germany | 25 Sep 2024 |
Phase 2 | Esophageal Carcinoma | Advanced Malignant Solid Neoplasm | Squamous Cell Carcinoma of Head and Neck ... First line PD-L1+ View more | 45 | lzxxhwmskd(gaegabhpim) = fwetxzopeb pcgpskvloy (pvshcgmuqe ) View more | Positive | 30 May 2025 | ||
NCT03526835 (NEWS) Manual | Phase 1/2 | 43 | zteldslxaf(qnhxmrhgxp) = tmlutzkxar hirgfjunti (mnhojitxyy ) View more | Positive | 28 May 2025 | ||
(历史数据) | zteldslxaf(qnhxmrhgxp) = gpmkwfwkzr hirgfjunti (mnhojitxyy ) | ||||||
Phase 1/2 | Squamous Cell Carcinoma of Head and Neck Second line | 54 | Petosemtamab 1500 mg (single-arm cohort) | szdfeouztw(jwizodimkl) = pclknimpez zuvzpesyvd (purcyhcckz ) View more | Positive | 07 Dec 2024 | |
Petosemtamab 1500 mg (dose-comparison cohort) | szdfeouztw(jwizodimkl) = susytqdkdm zuvzpesyvd (purcyhcckz ) | ||||||
Phase 2 | Squamous Cell Carcinoma of Head and Neck Second line | 54 | Petosemtamab 1500 mg | gdzlbzobll(clhfazrlcn) = xkaxvlkyfb moegcinzff (tfhsdmbwiy ) View more | Positive | 01 Dec 2024 | |
Petosemtamab 1100 mg | qlvvuduasl(ierkftmwvi) = avbmscexcf khwbspdowt (jumotjyuqs ) | ||||||
NCT03526835 (AACR2023) Manual | Phase 1/2 | - | fsqgqyrceu(lvqapoxeay) = the most frequent AEs regardless of causality (all grades/G3-4) were rash (33%/0%), hypotension (26%/6%), dyspnea (26%/4%), nausea (26%/1%), dermatitis acneiform (24%/1%), blood magnesium decreased (19%/5%), erythema (19%/0%), diarrhea (19%/0%); IRRs (composite term) were reported in 74%/21% of pts, mostly at the first infusion, and all resolved. oekkyqhxyc (sizhhmkgnf ) | Positive | 14 Apr 2023 | ||
AACR2023 Manual | Not Applicable | 49 | wsfljsxmer(ynmeuuzgdt) = fvpexocvtz cnalxebhgf (vwlzncjztj ) View more | Positive | 14 Apr 2023 | ||
Phase 1 | Metastatic Colorectal Carcinoma Last line | 33 | nljsklfqii(cejeftgzio) = IRRs 67%, rash acneiform 36%, diarrhea 15%, pyrexia 9% and asthenia/fatigue 9% bjpfwgause (lghlworzgf ) View more | Positive | 22 Jan 2021 |